The Life Sciences team advised Relay Therapeutics as it closed its $63 million Series B financing round. Proceeds from the financing will be used to advance Relay Therapeutics’ pipeline of oncology candidate medicines as they progress toward clinical trials. The investment will also support deeper integration of a platform that leverages both best-in-class experimental and computational technologies to discover and develop a pipeline of novel, protein motion-based therapies. Relay’s financing was led by BVF Partners, with participation from new investors GV (formerly Google Ventures), Casdin Capital, EcoR1 Capital and Section 32. Existing investors Third Rock Ventures and Alexandria Venture Investments also participated.
Relay Therapeutics is committed to discovering and developing medicines that will make a transformative difference for patients by building the first dedicated drug discovery pipeline centered on protein motion.
The Goodwin team was led by partners Mitchell Bloom and William Collins and included associates Gabriela Morales-Rivera and Jason Goldfarb.
For additional details on the financing, please read the press release.